(R)-3-methylisothiazolidine 1,1-dioxide → (R)-[4-(2,4-dimethylphenyl)piperazin-1-yl][2-methanesulfonyl-4-(3-methyl-1,1-dioxo-1lambda6-isothiazolidin-2-yl)phenyl]methanone
반응식
[CH3:1][C:2]1[CH:7]=[C:6]([CH3:8])[CH:5]=[CH:4][C:3]=1[N:9]1[CH2:14][CH2:13][N:12]([C:15]([C:17]2[CH:22]=[CH:21][C:20](I)=[CH:19][C:18]=2[S:24]([CH3:27])(=[O:26])=[O:25])=[O:16])[CH2:11][CH2:10]1.[CH3:28][C@@H:29]1[CH2:33][CH2:32][S:31](=[O:35])(=[O:34])[NH:30]1>>[CH3:1][C:2]1[CH:7]=[C:6]([CH3:8])[CH:5]=[CH:4][C:3]=1[N:9]1[CH2:14][CH2:13][N:12]([C:15]([C:17]2[CH:22]=[CH:21][C:20]([N:30]3[C@H:29]([CH3:28])[CH2:33][CH2:32][S:31]3(=[O:35])=[O:34])=[CH:19][C:18]=2[S:24]([CH3:27])(=[O:26])=[O:25])=[O:16])[CH2:11][CH2:10]1참가 물질
3
반응물 2
생성물 1
실험 절차
Using [4-(2,4-dimethylphenyl)piperazin-1-yl](4-iodo-2-methanesulfonylphenyl)methanone (886 mg) described in Preparation Example 157 and (R)-3-methylisothiazolidine 1,1-dioxide (240 mg) described in Preparation Example 2 and by the reaction and treatment in the same manner as in Example 1, the title compound (514 mg) was obtained.